Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revolution Medicines reports positive clinical progress and financial stability

Revolution Medicines made significant strides in clinical development and financial stability, despite anticipating increased expenses in 2023
Confidence in the efficacy and tolerability of RMC-6236 and RMC-6291, with a focus on optimizing dosing strategies for future development
Challenges include financial projections for 2023, patient evaluation discrepancies, and the need for more data on dose levels and response rates
Opportunities lie in exploring intermittent dosing, discussing specific response rates, and further data collection for dose optimization

Revolution Medicines reports promising antitumor activity and strengthens financial position

Revolution Medicines showcased progress in their innovative inhibitor programs, bolstered by a successful equity offering. While facing competition and addressing analyst concerns, the company is poised to deliver significant clinical updates and expand their data set for future growth.

Revolution Medicines reports Q2 progress, acquires EQRx for growth

Revolution Medicines showcased financial strength, pipeline progress, and strategic acquisitions, positioning the company for future growth.
While facing challenges in managing expenses and advancing drug candidates, opportunities in pivotal trials and partnerships present avenues for success.
Overall, Revolution Medicines remains optimistic about its clinical developments and financial stability, signaling a promising trajectory in the biopharmaceutical sector.

Revolution Medicines reports strong Q3 results and strategic investment plans

Revolution Medicines showcased promising drug results, bolstered its financial position through an acquisition, and emphasized strategic spending for value creation. Analyst inquiries highlighted the importance of clear communication and effective financial planning for future success.

Revolution Medicines reports robust 2023 performance and strategic growth

Revolution Medicines showcased strong financial performance and progress in 2023.
The company faces challenges in revenue and net loss but sees opportunities in global partnerships and drug combinations.
Strategic priorities for 2024 focus on advancing RAS inhibitors and expanding reach.
Overall, Revolution Medicines is positioned for growth despite facing financial and developmental challenges.

Revolution Medicines advances pivotal cancer trials amidst financial projections

Revolution Medicines is well-capitalized and focused on advancing key therapies.
Facing financial challenges but exploring partnerships and business growth.
Opportunities lie in expanding RMC-6236's efficacy and exploring new indications.

Revolution Medicines excels in Q2 with RAS(ON) inhibitor progress

Revolution Medicines' Q2 performance reflects strong advancements in oncology treatments, supported by a solid financial position and strategic leadership decisions.
While facing challenges in trial execution and financial management, the company's focus on innovation and growth presents significant opportunities for expansion.
Overall, Revolution Medicines is well-positioned to capitalize on the potential of its RAS(ON) inhibitor pipeline and drive future success in the biopharmaceutical industry.

Revolution Medicines reports Q3 loss but shows promise in cancer treatments

Revolution Medicines showcased progress in cancer treatments despite a net loss in Q3 2024. Strong cash reserves, promising data, and strategic collaborations position the company for future growth. Clear communication on financial strategies and upcoming milestones will be crucial for investor confidence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be a featured speaker in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference.

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress.

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

Simultaneous publication and presentation of RMC-6236 chemical structure, preclinical data and case studies during the “KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology" Session at AACR 2024 in San Diego Simultaneous publication and presentation of RMC-6236 chemical structure, preclinical data and case studies during the “KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology" Session at AACR 2024 in San Diego

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in preclinical models of RAS-mutant pancreatic ductal adenocarcinoma (PDAC)

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

Revolution Medicines, Inc. (RVMD) Q4 2023 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.63 per share a year ago.

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2023, and provided an update on corporate progress.

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2023 on Monday, February 26, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

The mean of analysts' price targets for Revolution Medicines, Inc. (RVMD) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?

REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will deliver a corporate presentation as part of the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. PT.

Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

Arcellx

CRISPR Therapeutics

The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval, many pharma companies prefer to play it safe rather than bet big.

Pharma's Frontline: 3 Stocks Driving Revolutionary Drug Development

Cerevel Therapeutics Holdings Inc

Vericel

InvestorPlace published an article last December about the seven hottest biotech stocks to own in 2023 and beyond. One of the seven was the SPDR S&P Biotech ETF (NYSEARCA: XBI ).

3 Biotech Stocks That Could Boom or Bust by 2025

Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines' Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs

Revolution Medicines Completes Acquisition of EQRx

REDWOOD CITY, Calif. and CAMBRIDGE, Mass.

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Erin Graves - Senior Director of Corporate Communications and IR Mark Goldsmith - Chairman and CEO Jack Anders - CFO Steve Kelsey - President of Research & Development Conference Call Participants Marc Frahm - TD Cowen Eric Joseph - JPMorgan Jonathan Chang - Leerink Partners Ami Fadia - Needham Alec Stranahan - Bank of America Operator Good day, and thank you for standing by. Welcome to the Revolution Medicines Q3 2023 Earnings Conference Call.

Revolution Medicines, Inc. (RVMD) Q3 2023 Earnings Conference Call Transcript

Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $0.87 per share a year ago.

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates

Promising clinical data for RMC-6236, a RAS MULTI (ON) Inhibitor, and RMC-6291, a RAS G12C (ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress

Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112 Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2023 on Monday, November 6, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

Revolution Medicines reported data from a phase 1 study of RMC-6236 in treating lung cancer and pancreatic cancer. High numbers of unconfirmed responses caused investors to be disappointed with the results.

Why Revolution Medicines Stock Is Crashing Today

Biotech stock Revolution Medicines collapsed Monday after unveiling disappointing test results for an experimental cancer treatment.

Revolution Crashes 43% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining.

Investor Webcast to be held Sunday, October 22 at 12:30 p.m. Eastern Time Investor Webcast to be held Sunday, October 22 at 12:30 p.m. Eastern Time

Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

Revolution Medicines, Inc. (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

News for Revolution Medicines Stock (RVMD)